Targeting the NO‐cGMP‐PDE5 pathway in COVID‐19 infection. The DEDALO project. (3rd July 2020)

• Record Type: Journal Article
• Authors: Isidori, Andrea M.; Giannetta, Elisa; Pofi, Riccardo; Venneri, Mary A.; Gianfrilli, Daniele; Campolo, Federica; Mastroianni, Claudio M.; Lenzi, Andrea; d'Ettorre, Gabriella
• Is Part Of: Andrology. Volume 9:Number 1(2021)
• Page Start: 33
• Page End: 38
• Publication Date: 2020-07-03
• Subjects: PDE5 inhibitors -- cytokine storm -- IL‐6 -- interstitial pneumonia -- type 2 diabetes mellitus -- pulmonary fibrosis; Andrology -- Periodicals; 616.65
• DOI: 10.1111/andr.12837
• Languages: English
• ISSNs: 2047-2919

Abstract

Abstract: Background: A pandemic outbreak of COVID‐19 has been sweeping the world since December. It begins as a respiratory infection that, mainly in men with diabetes or renal impairment, evolves into a systemic disease, with SARDS, progressive endothelial cell damage, abnormal clotting and impaired cardiovascular and liver function. Some clinical trials are testing biological drugs to limit the immune system dysregulation, "cytokines storm, " that causes the systemic complications of COVID‐19. The contraindications of these drugs and their cost raise concerns over the implications of their widespread availability. Objectives: Numerous clinical and experimental studies have revealed a role for the nitric oxide (NO)‐cyclic GMP‐phosphodiesterase type 5 (PDE5) pathway in modulating low‐grade inflammation in patients with metabolic diseases, offering cardiovascular protection. PDE5 inhibition favors an anti‐inflammatory response by modulating activated T cells, reducing cytokine release, lowering fibrosis, increasing oxygen diffusion, stimulating vascular repair. PDE5 is highly expressed in the lungs, where its inhibition improves pulmonary fibrosis, a complication of severe COVID‐19 disease. Materials and methods: We performed a systematic review of all evidence documenting any involvement of the NO‐cGMP‐PDE5 axis in the pathophysiology of COVID‐19, presenting the ongoing clinical trials aimed at modulating this axis, including our own "silDEnafil administration in DiAbetic and dysmetaboLic patients with COVID‐19 (DEDALO trial)." Results: The reviewed evidence suggests that PDE5 inhibitors could offer a new strategy in managing COVID‐19 by (i) counteracting the Ang‐II‐mediated downregulation of AT‐1 receptor; (ii) acting on monocyte switching, thus reducing pro‐inflammatory cytokines, interstitial infiltration and the vessel damage responsible for alveolar hemorrhage‐necrosis; (iii) inhibiting the transition of endothelial and smooth muscle cells to mesenchymal cells in the pulmonary artery, preventing clotting and thrombotic complications. Discussion and Conclusion: If the ongoing trials presented herein should provide positive findings, the low cost, wide availability and temperature stability of PDE5 inhibitors could make them a major resource to combat COVID‐19 in developing countries.